ArticleHypertension (Dallas, Tex. : 1979)2021
Renal Injuries in Primary Aldosteronism: Quantitative Histopathological Analysis of 19 Patients With Primary Adosteronism.
Open access · bronzeAbstract read
In one paragraph
Article in Hypertension (Dallas, Tex. : 1979), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Aldosterone excess, blood pressure control, and kidney outcomes in chronic kidney disease: findings from the Cardiovascular and Metabolic Disease Etiology Research Center-High Risk (CMERC-HI) Study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- [Primary aldosteronism as an independent factor of kidney damage. Potential therapeutic strategies and research prospects].Problemy endokrinologii · 2026Review
- Blood pressure patterns and cardio-renal complications in primary aldosteronism compared with essential hypertension in a tunisian population.Journal of human hypertension · 2026Article
- Primary aldosteronism.Nature reviews. Disease primers · 2026Review
- Unmasking primary aldosteronism after kidney transplantation: a case series.Journal of human hypertension · 2026Article
- Multiparametric diffusion-weighted MRI for renal microstructural assessment in patients with primary aldosteronism at varying direct renin concentrations.Abdominal radiology (New York) · 2026Article
- Noninvasive evaluation of renal oxygenation by blood oxygenation level-dependent magnetic resonance imaging in patients with primary aldosteronism.Scientific reports · 2025Article
- Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease.European heart journal · 2025Review
- Risk factors for renal impairment in primary aldosteronism: a retrospective study.Frontiers in endocrinology · 2025Article
- A comparative study of postadrenalectomy hyperuricemia and renal impairment in patients with unilateral primary aldosteronism: does histopathology subtype matter?BMC nephrology · 2024Article
- Kidney function predicts new-onset cardiorenal events and mortality in primary aldosteronism: approach of the 2021 race-free eGFR equation.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Observational
- Article
- Primary Aldosteronism in Chronic Kidney Disease: Blood Pressure Control and Kidney and Cardiovascular Outcomes After Surgical Versus Medical Management.Hypertension (Dallas, Tex. : 1979) · 2023Article
- Mineralocorticoid Receptor Antagonists for Preventing Chronic Kidney Disease Progression: Current Evidence and Future Challenges.International journal of molecular sciences · 2023Review
- Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments.Journal of the American Heart Association · 2023Article
- Synergistic effect of albuminuria on atherosclerosis in patients with primary aldosteronism.Therapeutic advances in chronic disease · 2023Article
- Article
- Impact of Primary Aldosteronism in Resistant Hypertension.Current hypertension reports · 2022Review
- Review
- Characteristics and Outcomes in Primary Aldosteronism Patients Harboring Glucocorticoid-Remediable Aldosteronism.Biomedicines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 13 institutions in 4 countries.
Hiroko OgataFrom the Department of Pathology (H.O., Y.Y., X.G., H. Sasano), Tohoku University Graduate School of Medicine, Sendai, Japan.
Yuto YamazakiFrom the Department of Pathology (H.O., Y.Y., X.G., H. Sasano), Tohoku University Graduate School of Medicine, Sendai, Japan.
Yuta TezukaDivision of Nephrology, Endocrinology, and Vascular Medicine (Y. Tezuka, K. Omata, Y. Ono, R.M., M.M., S.I., F.S.), Tohoku University Hospital, Sendai, Japan.
Xin GaoFrom the Department of Pathology (H.O., Y.Y., X.G., H. Sasano), Tohoku University Graduate School of Medicine, Sendai, Japan.
Kei OmataDivision of Clinical Hypertension, Endocrinology and Metabolism (Y. Tezuka, K. Omata, Y. Ono, F.S.), Tohoku University Graduate School of Medicine, Sendai, Japan.
Yoshikiyo OnoDivision of Clinical Hypertension, Endocrinology and Metabolism (Y. Tezuka, K. Omata, Y. Ono, F.S.), Tohoku University Graduate School of Medicine, Sendai, Japan.
Yoshihide KawasakiDivision of Urology (Y.K., A. Ito, Y.A.), Tohoku University Hospital, Sendai, Japan.
Tomoaki TanakaDepartment of Molecular diagnosis, Chiba University Graduate School of Medicine, Japan (T.T., H.N.).
Hidekazu NaganoDepartment of Molecular diagnosis, Chiba University Graduate School of Medicine, Japan (T.T., H.N.).
Norio WadaDepartment of Diabetes and Endocrinology, Sapporo City General Hospital, Japan (N.W.).
Yutaka OkiDepartment of Endocrinology and Metabolism, Hamamatsu University School of Medicine, Shizuoka, Japan (Y. Oki, A. Ikeya).
Akira IkeyaDepartment of Endocrinology and Metabolism, Hamamatsu University School of Medicine, Shizuoka, Japan (Y. Oki, A. Ikeya).
Kenji OkiDepartment of Molecular and Internal Medicine, Graduate School of Biochemical and Health Sciences, Hiroshima University Hospital, Japan (K. Oki).
Yoshiyu TakedaDepartment of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Japan (Y. Takeda, M.K.).
Mitsuhiro KometaniDepartment of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Japan (Y. Takeda, M.K.).
Kazunori KageyamaDepartment of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Japan (K.K., K.T.).
Ken TeruiDepartment of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Japan (K.K., K.T.).
Celso E Gomez-SanchezDivision of Endocrinology, Department of Medicine, The University of Mississippi Medical Center, Jackson (C.E.G.-S.).
Shujun LiuDepartment of Nephrology, The Second Hospital of Jilin University, Changchun, China (S.L.).
Ryo MorimotoDivision of Nephrology, Endocrinology, and Vascular Medicine (Y. Tezuka, K. Omata, Y. Ono, R.M., M.M., S.I., F.S.), Tohoku University Hospital, Sendai, Japan.
Kensuke JohDepartment of Pathology, The Jikei University School of Medicine, Tokyo, Japan (K.J.).
Hiroshi SatoDivision of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences, Sendai, Japan (H. Sato).
Mariko MiyazakiDivision of Nephrology, Endocrinology, and Vascular Medicine (Y. Tezuka, K. Omata, Y. Ono, R.M., M.M., S.I., F.S.), Tohoku University Hospital, Sendai, Japan.
Akihiro ItoDivision of Urology (Y.K., A. Ito, Y.A.), Tohoku University Hospital, Sendai, Japan.
Yoichi AraiDivision of Urology (Y.K., A. Ito, Y.A.), Tohoku University Hospital, Sendai, Japan.
Yasuhiro NakamuraDivision of Pathology, Faculty of medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan (Y.N.).
Sadayoshi ItoDivision of Nephrology, Endocrinology, and Vascular Medicine (Y. Tezuka, K. Omata, Y. Ono, R.M., M.M., S.I., F.S.), Tohoku University Hospital, Sendai, Japan.
Fumitoshi SatohDivision of Clinical Hypertension, Endocrinology and Metabolism (Y. Tezuka, K. Omata, Y. Ono, F.S.), Tohoku University Graduate School of Medicine, Sendai, Japan.
Hironobu SasanoFrom the Department of Pathology (H.O., Y.Y., X.G., H. Sasano), Tohoku University Graduate School of Medicine, Sendai, Japan.
Tohoku University · JPTohoku University Hospital · JPChiba University · JPHamamatsu University School of Medicine · JPHirosaki University · JPKanazawa University · JPTohoku Medical and Pharmaceutical University · JPDiabetes Australia · AUJikei University School of Medicine · JPOki Electric Industry (Japan) · JPSapporo City General Hospital · JPSecond Affiliated Hospital of Jilin University · CNUniversity of Mississippi Medical Center · US
Funding
Tracking and Evaluation CoreU54GM115428 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI MASON, SARAH · 2016 to 2025
$38.2MRegulation of Mineralocorticoid Receptor ActionI01BX004681 · VA · G V SONNY MONTGOMERY VA MEDCIAL CENTER · PI GOMEZ-SANCHEZ, CELSO ENRIQUE · 2021 to 2023
–BLRD VA I01 BX004681NIGMS NIH HHS U54 GM115428
Abstract
[Figure: see text].
Indexed as
AdultAgedAged, 80 and overEssential HypertensionFemaleHumansHyperaldosteronismKidneyMaleMiddle AgedMuscle, Smooth, VascularRetrospective Studies11βHSDaldosteronehistopathologyhypertensionmineralocorticoid receptorrenin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.